# A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

> **NCT06163040** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 7 (actual)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **DRUG:** Elotuzumab in combination with pomalidomide and dexamethasone
- **DRUG:** Elotuzumab in combination with lenalidomide and dexamethasone

## Key facts

- **NCT ID:** NCT06163040
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-22
- **Primary completion:** 2025-03-17
- **Final completion:** 2025-03-17
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06163040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06163040, "A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06163040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*